Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Proximagen losses grow on R&D drive

This article was originally published in Scrip

Executive Summary

Proximagen Neuroscience's net loss grew during the first half of 2008 as its capacity was diverted away from revenue generating service contracts and towards progressing its preclinical programmes. Pretax losses rose by £520,000 to £1.6 million following modest increases in R&D costs and lower service contract revenue. R&D costs were £1.4 million (+33%) following clinical work on its PRX5 programme in Parkinson's disease, while service contracts bought in £200,000, a decrease of £300,000. The UK company's results beat analysts' expectations at Canaccord Adams, which reiterated its buy recommendation for the firm's stock.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts